All In Biotech

Drug Trial Radar · NCT03787940

Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis

Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis Based on N-Acetyltransferase Type 2 Genotyping

Last checked: Nov 19, 2026Latest source record: Feb 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 676 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

676

Planned (sponsor's estimate)

Start

Mar 4, 2019

Primary completion

Dec 31, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Beijing Chest HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The genetically polymorphic N-acetyltransferase type 2 (NAT2) is responsible for isoniazid metabolism, and rapid acetylators were associated with low concentrations of isoniazid based on previous studies. The investigators hypothesize that among rapid acetylators high dose isoniazid would result in lower rates of death and disability in patients with tuberculous meningitis than the rates with the standard regimen. The investigators recruited patients between the ages of 18 and 65 years with newly diagnosed TBM, then NAT2 genotype will be characterized by using High-Resolution Melting Kit (Zeesan Company, Xiamen). Participants with slow or intermediate acetylators will be administered with standard chemotherapy. For participants with rapid acetylators, patients were stratified at study entry according to the modified British Medical Research Council criteria (MRC grade), then randomly assigned in a 1:1 ratio to receive either standard or with high dose isoniazid treatment. All patients received antituberculosis treatment, which consisted of isoniazid (standard dose or high dose), rifampin, pyrazinamide, ethambutol for 3 months, followed by isoniazid, rifampin and ethambutol at the same doses for an additional 9 months. All patients received adjunctive treatment with dexamethasone for the first 6 to 8 weeks of treatment. 338 participants with rapid acetylators were randomly assigned to group B (standard treatment) and group C (high dose isoniazid), respectively. At the same time, 338 participants with slow or intermediate acetylators were recruited to group A (standard treatment). The primary outcome was death or severe disability 12 months after enrollment. Secondary outcome measures were coma-clearance time, fever-clearance time, and difference of laboratory examination (protein concentration, chloride, glucose and white cell counts) of cerebrospinal fluid.

Conditions

  • Tuberculous Meningitis

Interventions

  • IsoniazidDrug

    standard dose isoniazid or high dose isoniazid for participants with rapid acetylators

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with death or severe disabilityTime frame: up to 12 months after enrollment

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital affiliated to Capital Medical University

    Beijing, China · Recruiting

  • Jiamusi Infectious Disease Hospital

    Jiamusi, China · Recruiting

  • Jiangxi Provincial Chest Hospital

    Nanchang, China · Recruiting

  • Zunyi Medical College affiliated Hospital

    Zunyi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.